Immunocore Holdings Ltd (IMCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.46 Million) by net assets ($396.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immunocore Holdings Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Immunocore Holdings Ltd (IMCR) total liabilities for a breakdown of total debt and financial obligations.
Immunocore Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunocore Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trevi Therapeutics Inc
NASDAQ:TRVI
|
-0.057x |
|
momo.com Inc
TW:8454
|
0.213x |
|
Mullen Group Ltd.
TO:MTL
|
0.052x |
|
Jiangling Motors Corp Ltd
SHE:000550
|
0.016x |
|
Beijing Water Business Doctor
SHE:300055
|
0.001x |
|
Yantai Tayho Advanced Materials Co Ltd
SHE:002254
|
0.045x |
|
HIAG Immobilien Holding AG
SW:HIAG
|
0.015x |
|
Is Yatirim Menkul Degerler AS
IS:ISMEN
|
0.047x |
Annual Cash Flow Conversion Efficiency for Immunocore Holdings Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of Immunocore Holdings Ltd from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Immunocore Holdings Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $360.72 Million | $26.06 Million | 0.072x | +806.40% |
| 2023-12-31 | $368.84 Million | $2.94 Million | 0.008x | +105.49% |
| 2022-12-31 | $338.90 Million | $-49.21 Million | -0.145x | +76.51% |
| 2021-12-31 | $231.53 Million | $-143.11 Million | -0.618x | +43.52% |
| 2020-12-31 | $55.35 Million | $-60.57 Million | -1.094x | +78.87% |
| 2019-12-31 | $19.57 Million | $-101.38 Million | -5.181x | -1663.12% |
| 2018-12-31 | $56.58 Million | $-16.63 Million | -0.294x | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more